Thromboxanesynthase抗体;Thromboxanesynthase Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human cerebrum tissue lysate, Primary antibody: P12610(ADCYAP1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P12610(ADCYAP1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Thromboxane synthase (TXAS) is a key enzyme in the arachidonic acid pathway, responsible for converting prostaglandin H2 into thromboxane A2 (TXA2), a potent mediator of platelet aggregation, vasoconstriction, and smooth muscle proliferation. Dysregulation of TXAS activity is linked to cardiovascular diseases, thrombosis, and inflammatory conditions. Antibodies targeting TXAS are critical tools for studying its expression, localization, and functional roles in both physiological and pathological processes.

TXAS antibodies are widely used in immunological assays, such as Western blotting, immunohistochemistry, and ELISA, to quantify enzyme levels in tissues or cell lysates. They help investigate TXAS involvement in diseases like atherosclerosis, hypertension, and cancer, where elevated TXA2 production may drive progression. Additionally, these antibodies aid in evaluating the efficacy of TXAS inhibitors, which are explored as therapeutic agents to reduce thrombotic risks.

Research using TXAS antibodies has revealed tissue-specific expression patterns, with high levels observed in platelets, lung, and kidney. Species-specific antibodies (human, mouse, rat) enable cross-disciplinary studies, including preclinical models. Challenges include distinguishing TXAS from related cytochrome P450 enzymes and ensuring specificity in complex biological samples. Overall, TXAS antibodies remain indispensable for unraveling the enzyme's role in health and disease, supporting both basic research and drug development efforts.